Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

J&J Relying On Oncology As Growth Driver, Led By Solid Imbruvica, Darzalex Launches

Executive Summary

Pharma says pipeline is poised to continue growth with 10 NMEs to be approved between 2015-2019 that could produce blockbuster sales. J&J adds that it’s planning 40 line extensions, with 10 that could yield $500m annually each.

Advertisement

Related Content

AbbVie/J&J's Imbruvica On Track For New Indication In Graft-Versus-Host Disease
Expanded US Approval Set To Take Janssen’s Darzalex Higher
J&J Maintains Strategy For Biosimilar Remicade As Inflectra Nears
Imbruvica Boosts CLL Lead With First-Line Claim
Janssen/Genmab Win 1st Anti-CD38 In Multiple Myeloma

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097507

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel